Merck & Co., Inc., Rahway, New Jersey, USA (the company) has added a news release to its website: 

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48

For full details, please visit the company's website.

To unsubscribe from this list, please visit the email alert section of the company's website.